C-Abl activates Janus kinase 2 in normal hematopoietic cells

Journal of Biological Chemistry

Volumn 289, Issue 31, 2014, Pages 21463-21472

  Tao, Wenjing ^a   Leng, Xiaohong ^a   Chakraborty, Sandip N ^a   Ma, Helen ^a   Arlinghaus, Ralph B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL DEATH; ENZYMES; SIGNAL TRANSDUCTION;

CO-IMMUNOPRECIPITATIONS; HEMATOPOIETIC CELL; HEMATOPOIETIC CELL LINE; KINASE ACTIVITY; KINASE INHIBITORS; OVER-EXPRESSION; PROTEIN EXPRESSIONS; STABLE COMPLEXES;

CHEMICAL ACTIVATION;

ABELSON KINASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMATINIB; INTERLEUKIN 3; INTERLEUKIN 5; JANUS KINASE 2; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; SHORT HAIRPIN RNA; JAK2 PROTEIN, MOUSE; PRIMER DNA;

32D CELL LINE; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; FLUORESCENCE; HEMATOPOIETIC CELL; IMMUNOPRECIPITATION; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; BONE MARROW CELLS; CELL LINE; CELL SURVIVAL; DNA PRIMERS; ENZYME ACTIVATION; INTERLEUKIN-3; JANUS KINASE 2; MICE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-ABL;

EID: 84905381781     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.554501     Document Type: Article

References (57)

1. Sandberg, E. M., Wallace, T. A., Godeny, M. D., VonDerLinden, D., and Sayeski, P. P. (2004) Jak2 tyrosine kinase: a true jak of all trades? Cell Biochem. Biophys. 41, 207-232
2. Reddy, E. P., Korapati, A., Chaturvedi, P., and Rane, S. (2000) IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 19, 2532-2547 (Pubitemid 30339209)
3. Shuai, K., and Liu, B. (2003) Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3, 900-911 (Pubitemid 37411719)
4. Vainchenker, W., and Constantinescu, S. N. (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32, 2601-2613
5. Herrington, J., and Carter-Su, C. (2001) Signaling pathways activated by the growth hormone receptor. Trends Endocrinol. Metab. 12, 252-257 (Pubitemid 33714215)
6. Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U., and Pfeffer, K. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409 (Pubitemid 28232084)
7. Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J. C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., Grosveld, G., and Ihle, J. N. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385-395 (Pubitemid 28232083)
8. Krempler, A., Qi, Y., Triplett, A. A., Zhu, J., Rui, H., and Wagner, K. U. (2004) Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis 40, 52-57 (Pubitemid 39655118)
9. Silvennoinen, O., Ungureanu, D., Niranjan, Y., Hammaren, H., Bandaranayake, R., and Hubbard, S. R. (2013) New insights into the structure and function of the pseudokinase domain in JAK2. Biochem. Soc. Trans. 41, 1002-1007
10. Yoshimura, A., Naka, T., and Kubo, M. (2007) SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7, 454-465 (Pubitemid 46834848)
11. Hansen, G., Hercus, T. R., McClure, B. J., Stomski, F. C., Dottore, M., Powell, J., Ramshaw, H., Woodcock, J. M., Xu, Y., Guthridge, M., McKinstry, W. J., Lopez, A. F., and Parker, M. W. (2008) The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 134, 496-507
12. Dey, R., Ji, K., Liu, Z., and Chen, L. (2009) A cytokine-cytokine interaction in the assembly of higher-order structure and activation of the interleukine-3:receptor complex. PLoS One 4, e5188
13. Hercus, T. R., Thomas, D., Guthridge, M. A., Ekert, P. G., King-Scott, J., Parker, M. W., and Lopez, A. F. (2009) The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 114, 1289-1298
14. Lindauer, K., Loerting, T., Liedl, K. R., and Kroemer, R. T. (2001) Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 14, 27-37 (Pubitemid 32318935)
15. Saharinen, P., Vihinen, M., and Silvennoinen, O. (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14, 1448-1459 (Pubitemid 36547413)
16. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., Scott, M. A., Erber, W. N., and Green, A. R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (Pubitemid 40386783)
17. James, C., Ugo, V., Le Couédic, J. P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J. L., Constantinescu, S. N., Casadevall, N., and Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148 (Pubitemid 40663494)
18. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., and Skoda, R. C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (Pubitemid 40570926)
19. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., Adelsperger, J., Koo, S., Lee, J. C., Gabriel, S., Mercher, T., D'Andrea, A., Fröhling, S., Döhner, K., Marynen, P., Vandenberghe, P., Mesa, R. A., Tefferi, A., Griffin, J. D., Eck, M. J., Sellers, W. R., Meyerson, M., Golub, T. R., Lee, S. J., and Gilliland, D. G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397 (Pubitemid 40544655)
20. Kirk, R. (2012) Haematological cancer: Hit the lymphoma, JAK. Nat. Rev. Clin. Oncol. 9, 608
21. Levine, R. L., Pardanani, A., Tefferi, A., and Gilliland, D. G. (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 7, 673-683 (Pubitemid 47327415)
22. Levine, R. L., Loriaux, M., Huntly, B. J., Loh, M. L., Beran, M., Stoffregen, E., Berger, R., Clark, J. J., Willis, S. G., Nguyen, K. T., Flores, N. J., Estey, E., Gattermann, N., Armstrong, S., Look, A. T., Griffin, J. D., Bernard, O. A., Heinrich, M. C., Gilliland, D. G., Druker, B., and Deininger, M. W. (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106, 3377-3379 (Pubitemid 41609169)
23. Mercher, T., Wernig, G., Moore, S. A., Levine, R. L., Gu, T. L., Fröhling, S., Cullen, D., Polakiewicz, R. D., Bernard, O. A., Boggon, T. J., Lee, B. H., and Gilliland, D. G. (2006) JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 108, 2770-2779
24. Malinge, S., Ben-Abdelali, R., Settegrana, C., Radford-Weiss, I., Debre, M., Beldjord, K., Macintyre, E. A., Villeval, J. L., Vainchenker, W., Berger, R., Bernard, O. A., Delabesse, E., and Penard-Lacronique, V. (2007) Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 109, 2202-2204 (Pubitemid 46348223)
25. Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., Warren, A. J., Gilliland, D. G., Lodish, H. F., and Green, A. R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459-468 (Pubitemid 46193073)
26. Levine, R. L., and Gilliland, D. G. (2008) Myeloproliferative disorders. Blood 112, 2190-2198
27. Samanta, A. K., Chakraborty, S. N., Wang, Y., Kantarjian, H., Sun, X., Hood, J., Perrotti, D., and Arlinghaus, R. B. (2009) Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 28, 1669-1681
28. Samanta, A. K., Lin, H., Sun, T., Kantarjian, H., and Arlinghaus, R. B. (2006) Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 66, 6468-6472 (Pubitemid 44085597)
29. Xie, S., Lin, H., Sun, T., and Arlinghaus, R. B. (2002) Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21, 7137-7146 (Pubitemid 35305600)
30. Xie, S., Wang, Y., Liu, J., Sun, T., Wilson, M. B., Smithgall, T. E., and Arlinghaus, R. B. (2001) Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20, 6188-6195 (Pubitemid 32964431)
31. Samanta, A., Perazzona, B., Chakraborty, S., Sun, X., Modi, H., Bhatia, R., Priebe, W., and Arlinghaus, R. (2011) Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25, 463-472
32. Dawson, M. A., Bannister, A. J., Göttgens, B., Foster, S. D., Bartke, T., Green, A. R., and Kouzarides, T. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin. Nature 461, 819-822
33. Van Etten, R. A. (1999) Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. 9, 179-186
34. Lanier, L. M., and Gertler, F. B. (2000) From Abl to actin: Abl tyrosine kinase and associated proteins in growth cone motility. Curr. Opin. Neurobiol. 10, 80-87 (Pubitemid 30102859)
35. Pendergast, A. M. (2002) The Abl family kinases: mechanisms of regulation and signaling. Adv. Cancer Res. 85, 51-100
36. Glover, R. T., Angiolieri, M., Kelly, S., Monaghan, D. T., Wang, J. Y., Smithgall, T. E., and Buller, A. L. (2000) Interaction of the N-methyl-D-aspartic acid receptor NR2D subunit with the c-Abl tyrosine kinase. J. Biol. Chem. 275, 12725-12729 (Pubitemid 30241424)
37. Lewis, J. M., Baskaran, R., Taagepera, S., Schwartz, M. A., and Wang, J. Y. (1996) Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc. Natl. Acad. Sci. U.S.A. 93, 15174-15179
38. Plattner, R., Kadlec, L., DeMali, K. A., Kazlauskas, A., and Pendergast, A. M. (1999) c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13, 2400-2411 (Pubitemid 29453611)
39. Zipfel, P. A., Grove, M., Blackburn, K., Fujimoto, M., Tedder, T. F., and Pendergast, A. M. (2000) The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19. J. Immunol. 165, 6872-6879 (Pubitemid 32001156)
40. Greuber, E. K., Smith-Pearson, P., Wang, J., and Pendergast, A. M. (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat. Rev. Cancer 13, 559-571
41. Pardanani, A., Hood, J., Lasho, T., Levine, R. L., Martin, M. B., Noronha, G., Finke, C., Mak, C. C., Mesa, R., Zhu, H., Soll, R., Gilliland, D. G., and Tefferi, A. (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21, 1658-1668 (Pubitemid 47086756)
42. Zhao, H., Chen, M. S., Lo, Y. H., Waltz, S. E., Wang, J., Ho, P. C., Vasiliauskas, J., Plattner, R., Wang, Y. L., and Wang, S. C. (2013) The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. Oncogene 33, 1429-1437
43. Chakraborty, S., Lin, Y. H., Leng, X., Miranda, R. N., Medeiros, L. J., Shpall, E., and Arlinghaus, R. B. (2013) Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase. Blood Cancer J. 3, e142
44. Nyfeler, B., Michnick, S. W., and Hauri, H. P. (2005) Capturing protein interactions in the secretory pathway of living cells. Proc. Natl. Acad. Sci. U.S.A. 102, 6350-6355 (Pubitemid 40617446)
45. Ling, X., Ma, G., Sun, T., Liu, J., and Arlinghaus, R. B. (2003) Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr. Cancer Res. 63, 298-303 (Pubitemid 36152483)
46. Tao, W. J., Lin, H., Sun, T., Samanta, A. K., and Arlinghaus, R. (2008) BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene 27, 3194-3200 (Pubitemid 351693174)
47. Quelle, F. W., Sato, N., Witthuhn, B. A., Inhorn, R. C., Eder, M., Miyajima, A., Griffin, J. D., and Ihle, J. N. (1994) JAK2 associates with the β c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol. Cell. Biol. 14, 4335-4341
48. Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Yi, T., Tang, B., Miura, O., and Ihle, J. N. (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74, 227-236 (Pubitemid 23221699)
49. Silvennoinen, O., Witthuhn, B. A., Quelle, F. W., Cleveland, J. L., Yi, T., and Ihle, J. N. (1993) Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. U.S.A. 90, 8429-8433 (Pubitemid 23277682)
50. Argetsinger, L. S., Campbell, G. S., Yang, X., Witthuhn, B. A., Silvennoinen, O., Ihle, J. N., and Carter-Su, C. (1993) Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74, 237-244 (Pubitemid 23221700)
51. Campbell, G. S., Argetsinger, L. S., Ihle, J. N., Kelly, P. A., Rillema, J. A., and Carter-Su, C. (1994) Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants. Proc. Natl. Acad. Sci. U.S.A. 91, 5232-5236 (Pubitemid 24174300)
52. Huang, H. M., Lin, Y. L., Chen, C. H., and Chang, T. W. (2005) Simultaneous activation of JAK1 and JAK2 confers IL-3 independent growth on Ba/F3 pro-B cells. J. Cell Biochem. 96, 361-375
53. Moresco, E. M. (2006) in Abl Family Kinases in Development and Disease (Koleske, A. J., ed) pp. 1-120, Landes Bioscience, Austin, TX
54. Plattner, R., Koleske, A. J., Kazlauskas, A., and Pendergast, A. M. (2004) Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol. Cell. Biol. 24, 2573-2583 (Pubitemid 38326010)
55. Lu, X., Huang, L. J., and Lodish, H. F. (2008) Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J. Biol. Chem. 283, 5258-5266
56. Pradhan, A., Lambert, Q. T., Griner, L. N., and Reuther, G. W. (2010) Activation of JAK2-V617F by components of heterodimeric cytokine receptors. J. Biol. Chem. 285, 16651-16663
57. Lin, J., Sun, T., Ji, L., Deng, W., Roth, J., Minna, J., and Arlinghaus, R. (2007) Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26, 6989-6996 (Pubitemid 350014606)